Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase II Study to Evaluate the Safety of Standard Induction and Consolidation Therapy in Combination With Dasatinib in Newly Diagnosed Adult Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

NCT01724879 is registered in ClinicalTrials.gov with Goethe University as lead sponsor.

NCT NCT01724879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01724879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase II Study to Evaluate the Safety of Standard Induction and Consolidation Therapy in Combination With Dasatinib in Newly Diagnosed Adult Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)
Lead sponsor
Goethe University
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
September 30, 2015
Enrollment
19 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

philadelphia positive acute lymphoblastic leukemia